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Introduction {#sec001}
============

Breast cancer is the most common malignancy and is the major cause of cancer death among women worldwide \[[@pone.0232519.ref001]\]. It is a heterogeneous disease with a variety of subtypes, each characterized by distinct clinical, pathologic and molecular features \[[@pone.0232519.ref002]\]. The widely accepted predictive or/and prognostic factors in breast cancer include steroid or growth hormone receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER-2) \[[@pone.0232519.ref003], [@pone.0232519.ref004]\]. Understanding the role of steroid hormone receptors in breast cancer has led to the development of hormonal therapy which generally have less side effect when compared to chemotherapy \[[@pone.0232519.ref003], [@pone.0232519.ref005]\]. In addition, targeted therapies to human epidermal growth factor receptor type 2 (HER-2) positive tumors were developed through continuous improvement in the understanding of the molecular biology of breast cancer \[[@pone.0232519.ref006]\].

The role of androgen receptor (AR) in prostate cancer is well established and AR targeted drugs are currently part of the standard care positively affecting the course and outcome of the disease \[[@pone.0232519.ref007], [@pone.0232519.ref008]\]. However, the role of AR in breast cancer is emerging only recently because of the increased interest among researchers in breast cancer to understand a disease which is so heterogenous in its molecular feature and limited treatment options \[[@pone.0232519.ref007]--[@pone.0232519.ref009]\]. An increasing number studies evaluated AR as a useful marker for the further refinement of breast cancer molecular subtype and as an emerging clinical target \[[@pone.0232519.ref010], [@pone.0232519.ref011]\]. Some authors suggested assessment of Androgen receptor in breast cancer in the routine diagnosis, as part of a quadruple panel alongside the assessment of ER, PR, and HER2 to serve as an additional predictive and/or prognostic marker \[[@pone.0232519.ref011], [@pone.0232519.ref012]\].

AR is expressed in all stages of breast cancer (in-situ, primary and metastatic disease) \[[@pone.0232519.ref013]\] and several studies show AR may play different prognostic role in ER-positive and ER-negative breast cancers \[[@pone.0232519.ref007], [@pone.0232519.ref008], [@pone.0232519.ref014]\]. In ER-positive breast cancer, AR was reported to predict favorable disease outcome consistently. Co-expressing AR and ER in breast cancer improved disease-free survival (DFS) and overall survival (OS) significantly \[[@pone.0232519.ref008], [@pone.0232519.ref014], [@pone.0232519.ref015]\]. In ER-positive tumors, AR seems to inhibit the cellular proliferation induced by estradiol and to have a favorable prognostic value \[[@pone.0232519.ref008], [@pone.0232519.ref012], [@pone.0232519.ref015], [@pone.0232519.ref016]\]. However, in ER-negative breast cancers AR may be able to drive disease progression and may be linked to poor prognosis \[[@pone.0232519.ref010], [@pone.0232519.ref017], [@pone.0232519.ref018]\].

Preclinical and clinical studies conducted in recent years are supporting the role of AR-targeting treatment in the management of breast cancer \[[@pone.0232519.ref009], [@pone.0232519.ref013], [@pone.0232519.ref016], [@pone.0232519.ref019]\]. Therefore, both AR antagonists and AR agonists will likely become useful and safe options of treatment in various breast cancer subtypes particularly in combination with other agents already proved to be beneficial in treating breast cancer, but only the ongoing and future prospective clinical trials will allow us to establish which agents are the best options in every specific condition \[[@pone.0232519.ref008], [@pone.0232519.ref009], [@pone.0232519.ref013], [@pone.0232519.ref016], [@pone.0232519.ref020]--[@pone.0232519.ref022]\].

Most of the studies conducted to characterize the expression of AR so far are done in the western countries and shows AR is expressed in approximately 80 and 60% of primary and metastatic breast tumors, respectively. The frequency of AR expression in those studies varies across the clinical subtypes, approximately 84--95% in ER+ tumors, 50--63% in ER−/HER2+ tumors, and 10--53% in TNBC \[[@pone.0232519.ref008], [@pone.0232519.ref014], [@pone.0232519.ref017], [@pone.0232519.ref021]--[@pone.0232519.ref023]\].

Only few studies have been conducted in Africa to characterize Androgen receptor (AR) in breast tumor. One of the study done among Tanzanians by Bravaccini et.al in 2018 \[[@pone.0232519.ref024]\] reported an overall frequency of AR-positivity at \>1% cut-off value to be 66% and another done among Ghanaians by Proctor E et.al. in 2015 \[[@pone.0232519.ref025]\] reported an overall frequency of AR-positivity at \>10% cut-off value to be 44%. This study is a continuation of our previous work in molecular classification of breast cancer among Ethiopian women \[[@pone.0232519.ref026]\]. We observed that breast cancer in Ethiopian patients at time of diagnosis are majorly hormone receptor positive unlike other African patients and we observed that the biological characteristics of breast cancer among Africans is not homogenous which has a huge impact on breast cancer prevention and treatment in the continent. Therefore, our present study aimed to determine the prevalence of AR expression and its association with clinicopathological parameters in Ethiopian breast cancer patients.

Materials and methods {#sec002}
=====================

The study was approved by Institutional Review Board (IRB) of Faculty of Medicine, Addis Ababa University. Ethical approval was obtained from SPHMMC to collect archived FFPE tissue samples from enrolled patients. The study was also approved by the National Research Ethics Review Committee at the Ethiopian ministry of Science and Technology. Written informed consent was obtained from every patient and all tissue samples were fully anonymized before accessed. Medical records of patients who undergone surgery between October 2012 and December 20l5 were accessed to collect sociodemographic and pathological data. These cohorts were also used for our previous published work aimed at assessment of the frequency and distribution of molecular subtypes of breast cancer in Ethiopian women \[[@pone.0232519.ref026]\].

This study was a cross sectional retrospective in design and recruited participants who visited the Oncology Centre at the Tikur Anbessa Specialized Hospital (TASH) which is referral hospital found in Addis Ababa, Ethiopia. Patients were enrolled based on availability of FFPE tissue either at TASH or St. Paul's Hospital Millennium Medical College (SPHMMC) which is also a public referral hospital in the capital where some of our participants had their pathology tests done. Patient medical records were accessed by the investigators to collect variables which includes age, tumor type, grade and stage of disease. Initially, a total of 189 patients were included in the study but 66 cases were excluded because of issues related to availability or quality of FFPE tissue samples. The final number of cases consisted of 123 patients and all archived FFPE blocks were sectioned, H&E stained and examined by a pathologist at Orebro Hospital in Sweden for locating tumors in the block to be used for constructing tissue microarray (TMA). The total number of cases, after TMA construction, to proceed with the molecular analysis were 114.

Before TMA construction, digital images for constructing TMA were taken from slides scanned with a Pannoramic 250 digital scanner (3D HISTECH Ltd., Budapest, Hungary) and representative areas selected from images using the software program 'Case viewer' (3D HISTECH Ltd., Budapest, Hungary). TMA grand master automated system (3DHISTECH Ltd., Budapest, Hungary) were used to construct the TMA. The size of TMA biopsy punches was 0.6-millimeter and it was prepared in triplicate from corresponding area marked by a pathologist. The punches were then taken from donor paraffin blocks and merged into TMA recipient paraffin blocks.

TMA slides were stained with monoclonal antibodies specified in "[Table 1](#pone.0232519.t001){ref-type="table"}" following standard protocols in automated system using the Dako Autostainer Link. Briefly, following deparaffinization and rehydration, heat induced epitope retrieval was performed with FLEX TRS High pH Retrieval buffer for 20 minutes. After peroxidase blocking, the specific monoclonal antibodies were applied at room temperature for 20 minutes. Detection was made using the FLEX + Rabbit EnVision System. DAB chromogen was then applied for 10 minutes. Finally, Slides were counterstained with Mayers hematoxylin for 5 seconds and then dehydrated and coverslipped.

10.1371/journal.pone.0232519.t001

###### Sources and dilutions of primary antibodies.

![](pone.0232519.t001){#pone.0232519.t001g}

  Antibody   Clone        Manufacturer   Dilution
  ---------- ------------ -------------- ----------
  ER         EP1          Agilent Dako   RTU
  PR         PgR1294      Agilent Dako   RTU
  Ki-67      Mib-1        Agilent Dako   RTU
  Her-2      Herceptest   Agilent Dako   RTU
  AR         EP120        Epitomics      1/100

RTU = Ready to use

Amplification of HER2 was evaluated using PATH Vysion (HER-2/CEP17) FISH Probe Kit from Abbott Molecular, Des Plaines, IL. Briefly, slides for FISH testing were deparaffinized, rinsed in absolute alcohol, and air dried. The sections were then subjected to pretreatment according to the manufacturer's protocol. Slides were hybridized with a probe mix in HYBrite (Vysis, Des Plaines, IL) where denaturation was set at 6 min at 73° C and hybridization for 17 hr at 37° C. Images were scored using the software program 'Case viewer' (3D HISTECH Ltd., Budapest, Hungary) after slides were scanned on a Pannoramic MIDI digital scanner (3D HISTECH Ltd., Budapest, Hungary). Signals from 20 tumor cells were evaluated for scoring HER2 amplification.

The expression of ER, PR, and HER2 were evaluated and scored using a standard criterion. A cutoff value of 1% was used to define ER and PR positivity based on the ASCO/CAP 2013 guidelines \[[@pone.0232519.ref027]\]. HER2 was graded based on the degree of membrane staining, on a scale of 0--3 based on recommendations from Fitzgibbons et. al \[[@pone.0232519.ref028]\]. Grades of 0--1+ are considered negative, a grade of 2+ is equivocal, and a grade of 3+ is considered positive for HER2 labeling. FISH for HER-2 amplification was considered positive when HER2:CEP17 ratios is ≥ 2:0. A Ki67 cut-off value of 20% in a minimum of 500 cells was used to define a high score as described in St. Gallen international panel of experts' recommendation \[[@pone.0232519.ref029]\]. A cutoff value of 1% nuclear staining was used to define AR positivity irrespective of intensity as previously described by Asano et.al. \[[@pone.0232519.ref030], [@pone.0232519.ref031]\].

Based on the IHC results and confirmation of HER2 amplification by FISH analysis., the tumors were classified into the following four molecular sub-types according to the St. Gallen international expert's consensus 2013 \[[@pone.0232519.ref029]\]: luminal A (ER and/or PR-positive, HER2-negative and Ki67\<20%), luminal B (ER and/or PR-positive, HER2-positive OR ER and/or PR-positive, HER2-negative and Ki67≥20%), HER2-enriched (ER and PR-negative, HER2 positive) and triple-negative (ER-negative, PR-negative and HER2-negative).

Statistical analysis {#sec003}
--------------------

Statistical analysis was done using SPSS for windows version 21. Continuous data are reported as mean ± SD or Number (proportions). Skew distributions are reported as the median value with minimum and maximum. All P values are two tailed and P value \< 0.05 was considered statistically significant. The Mann-Whitney U test was used to compare median age. Chi-square test and ANOVA were used to determine correlations.

Results and discussion {#sec004}
======================

There were 114 participants with samples available in acceptable quality for pathological and molecular test in this study. Mean age at diagnosis of the participants was 43 years (SD 14) and median age was 40 (range 22--75). Most of the study participants (40%) were \< 40 years old. In this study, 31% of the participants were ≥ 50 years and only 19% were 40--49 years old. "[Table 2](#pone.0232519.t002){ref-type="table"}" shows basic pathological and molecular characteristics of the study subjects.

10.1371/journal.pone.0232519.t002

###### Baseline clinicopathological and molecular characteristics of the study participants (n = 114).
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  Variables                   N (%)
  --------------------------- ---------
  **Histological Grade**      
  I                           7 (6)
  II                          32 (28)
  III                         39 (34)
  Missing                     36 (32)
  **Estrogen Receptor**       
  Positive                    74 (65)
  Negative                    40 (35)
  **Progesterone Receptor**   
  Positive                    49 (43)
  Negative                    64 (56)
  Missing                     1 (1)
  **HER2**                    
  Positive                    26 (23)
  Negative                    87 (76)
  Missing                     1 (1)
  AR                          
  Positive                    91 (80)
  Negative                    21 (18)
  Missing                     2 (2)
  **Histological Type**       
  Infiltrating Ductal         67 (59)
  Lobular                     6 (5)
  Others/Not classified       25 (22)
  Missing                     16 (14)
  **Stage**                   
  I                           19 (17)
  II                          37 (33)
  III                         36 (31)
  IV                          4 (3)
  Missing                     18 (16)

A total of 112 cases had complete data concerning AR immunostaining. These cases were classified as positive and negative as previously done by Asano et al., 2017 \[[@pone.0232519.ref030]\]. A representative image of the immunostaining is presented in "[Fig 1](#pone.0232519.g001){ref-type="fig"}". Out of 112 participants, 91 (81%) were positive for AR expression. The remaining 21 participants (19%) were negative for AR expression. "Tables [3](#pone.0232519.t003){ref-type="table"} and [4](#pone.0232519.t004){ref-type="table"}" shows the distribution of clinicopathological and molecular parameters in AR expressing and non-expressing tumors. "Tables [3](#pone.0232519.t003){ref-type="table"} and [4](#pone.0232519.t004){ref-type="table"}" also explores association of AR expression with variable clinical and molecular parameters among AR+ and AR- tumors. There was no statistically significant difference in the distribution of the clinicopathological parameters between AR expressing and non-expressing tumors.

![Representative images of AR positive immunohistochemistry in breast tumor tissue array.\
**A**, H&E staining (10X); **B**, immunostaining (10X); **C**, immunostaining of a specific area (40X).](pone.0232519.g001){#pone.0232519.g001}

10.1371/journal.pone.0232519.t003

###### Association between AR expression and clinicopathological parameters among the study participants.
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  Clinico-pathological parameters        AR Negative   AR Positive   Total     p-value
  -------------------------------------- ------------- ------------- --------- ---------
  **Median age at Diagnosis(min-max)**   44 (29--70)   40 (22--75)             0.218
  **Tumor Grade, n (%)**                                                       
  I                                      1 (6)         6 (10)        7 (9)     
  II                                     8 (47)        23 (39)       31 (39)   0.774
  III                                    8 (47)        30(51)        38 (48)   
  **Stage, n (%)**                                                             
  I                                      3 (16)        16 (21)       19 (20)   
  II                                     5 (26)        30 (41)       35 (38)   0.507
  III                                    10 (53)       26 (34)       36 (38)   
  IV                                     1 (3)         3 (4)         4 (4)     
  **Histological Type, n (%)**                                                 
  Infiltrating ductal                    17 (85)       49 (65)       66 (69)   0.169
  Lobular                                0 (0)         6 (8)         6 (6)     
  Others/Unknown                         3 (15)        21 (27)       24 (25)   

10.1371/journal.pone.0232519.t004

###### Association between AR and molecular parameters among the study participants.
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  Molecular parameters           AR Negative   AR Positive   Total     p-value
  ------------------------------ ------------- ------------- --------- --------------------------------------------
  **ER, n (%)**                                                        
  Negative                       15 (75)       23 (25)       38 (34)   0.000[\*](#t004fn001){ref-type="table-fn"}
  Positive                       5 (25)        68 (75)       73 (66)   
  **PR, n (%)**                                                        
  Negative                       19 (95)       44 (48)       63 (53)   
  Positive                       1 (5)         47 (52)       48 (43)   0.000[\*](#t004fn001){ref-type="table-fn"}
  **HER2, n (%)**                                                      
  Negative                       17 (89)       67 (74)       84 (76)   
  Positive                       2 (11)        24 (26)       26 (24)   0.145
  **Molecular Subtype, n (%)**                                         
  Luminal A                      4 (21)        41 (45)       45 (41)   
  Luminal B                      1 (5)         28 (31)       29 (26)   
  HER2-enriched                  1 (5)         10 (11)       11 (10)   0.000[\*](#t004fn001){ref-type="table-fn"}
  TNBC/basal-like                13 (68)       12 (13)       25 (23)   

\*P≤0.05

In this study, AR was expressed in 81% of breast tumors which is higher than the expression rates of both ER and PR. This result is comparable to previous studies conducted in other parts of the world mainly in the western countries (70--90%) \[[@pone.0232519.ref008], [@pone.0232519.ref014], [@pone.0232519.ref017], [@pone.0232519.ref021]--[@pone.0232519.ref023]\]. However, our result is different than the two African studies conducted in Ghana and Tanzania which was 44% and 66% respectively \[[@pone.0232519.ref024], [@pone.0232519.ref025]\]. The reason for the variation between our study (overall AR-positivity of 81%) and the Tanzanian study (overall AR-positivity of 66%) could be due to true biological difference in tumor characteristics in the two countries or methodological difference including variation in antibody clones used and sample size The variation in AR-positivity between our study and the Ghanaian study (overall AR-positivity 44%) could be also be both technical and biological differences because the Ghanaian study used \>10% cut-off value for AR-positivity and it is obvious that the frequency of AR-positivity would have been much higher if the now commonly used \>1% cut-off value which was applied in our study has been applied in their analysis.

Our study showed 93% of ER positive breast cancers cases also express AR. This is in line with previous studies among Caucasians (84--95%) but we couldn't compare our result with the Tanzania study because the investigators didn't present comparison by ER status \[[@pone.0232519.ref008], [@pone.0232519.ref014], [@pone.0232519.ref017], [@pone.0232519.ref021]--[@pone.0232519.ref023]\]. Similarly, comparison by ER status between our study and the Ghanaian study were not possible because the researchers didn't present their data separately for ER rather were reported for ER/PR as an aggregate. In our study, there was a statistically significant variation (P\<0.05) in the proportion of AR positivity between ER-positive (93%) and ER-negative (60%) tumors. This result is in line with previous observations in the western studies and reveals majority of ER positive tumors in our cohort co-express AR which according to accumulating evidences has beneficiary role \[[@pone.0232519.ref008], [@pone.0232519.ref014], [@pone.0232519.ref017], [@pone.0232519.ref021]--[@pone.0232519.ref023]\]. We were unable to do comparison between our study and the two African studies for AR expression with ER status because of absence of such information in those studies. There was a statistically significant variation (P\<0.05) in the proportion of AR positive cases between PR-positive (98%) and PR-negative (70%) tumors as well. This is also in line with previous observations \[[@pone.0232519.ref032]\]. There was no statistically significant variation in the expression of AR between HER2-positive and HER2-negative tumors in this study (P = 0.145). About 83% of HER2+/ER- tumors were positive for AR in this study which is higher than previous studies among Caucasians (50--63%) \[[@pone.0232519.ref033], [@pone.0232519.ref034]\]. The reason for this difference could be due to small number of HER2+/ER- tumors (only 12 cases) in our study.

The expression of AR among TNBC in our study was 48% which is comparable with both the Tanzanian study (54%) and reports among Caucasians (10--53%) \[[@pone.0232519.ref030], [@pone.0232519.ref035]\] but is significantly different than the proportion among Nigerian TNBC patients (8.3%) reported by Bhattarai et. al. in their recent global AR study \[[@pone.0232519.ref036]\]. The difference in AR expression among TNBC patients between our study and Nigerians in the Bhattarai et. al. study could be population variation in AR expression among the two countries. The expression of AR in our study among the other molecular subtypes was significantly different (P\<0.05) which is also in line with previous studies in the western countries \[[@pone.0232519.ref008], [@pone.0232519.ref032], [@pone.0232519.ref037]\]. No statistically significant correlation was found between the clinicopathological parameters and AR expression in this study.

Conclusion {#sec005}
==========

Androgen receptor (AR) is expressed in a significant number of most types of breast cancers and is more frequently expressed than ER and PR. Our study shows AR expression is significantly high among ER+ breast cancer patient. Similarly, AR is expressed in a significant number of triple-negative breast cancers. These indicates that breast cancers patients from Ethiopia may have favorable prognosis and could also benefit from progresses in AR targeted treatments under development. Since AR expression has important consequences on the prognosis and treatment of breast cancer, further studies with an increased number of samples is necessary to confirm our reports.
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======================
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The submitted manuscript needs significant editing regarding grammar and clarity. The first part of the discussion is almost a word-for-word repeat of the introduction instead of a summary of the study and overall findings. Also, there is no need to include a statement saying that you aren\'t going to re-hash the methods portion of the previous study. Either briefly describe the methods from the previous study with explanation of AR specific portions of these methods and reference to your previous study, or re-write the methods. It seems that you have re-written the methods anyway.

Please do not use the word \"about\" when you are referring to the number of samples. Give the absolute number and describe in detail what it means for a sample to be \"evaluable.\"

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0232519.r002

Author response to Decision Letter 0

11 Jan 2020

Reviewer 1

We thank the reviewer for the valuable comments!

Please find our responses:

1\. While most clinical trial report the use of specific antibody (AR 441 from DAKO) to address the antibody related controversy over variable AR expression, the authors' do not provide any rationale for using a different antibody for staining AR. Moreover, looking at micrographs showing AR staining in Figure 1, it seems that there is a huge amount of background/non-specific staining and scoring these type of staining may have a false positive results. The authors might have to provide micrographs for positive and negative controls used.

\>\>\> We don't have any special reason to use the Anti androgen receptor antibody clone EP 120 from Epitomics. It was the clone available in the laboratory at the time. We have supplied the micrograph for the positive and negative controls used in the study.

2\. Multiple factors like sample procuring method, antibody used to stain and method of staining and scoring (different cut off values) dictate the discrepancy in the results of expression of AR in TNBC. The paper do not address any of these issues.

\>\>\> The comment is correct, and we have addressed the issue under our discussion part in paragraph 4 page 12.

3\. There is a recent paper from Bhattarai et.al on prognostic role of AR in global TNBC cohort where the authors talk about AR expression in various cohorts including African cohort. It would be worth including the paper in the discussion.

\>\>\>We have included the paper in our discussion.

4\. Since Breast cancer patients of African ancestry have aggressive TNBC phenotype, it would be worth looking at the survival trend between AR+ and AR- TNBCs.

\>\>\>This is a very good recommendation and would consider comparing survival in other study.

5\. In addition, the manuscript has instances of awkward English and stylistic concerns so it would be great if the authors pay a little attention on spelling and sentence constructions.

\>\>\>We think this is addressed in the revision

Reviewer 2

We thank the reviewer for valuable comments!

Please find our responses:

1\. Table 3 shows that there are no significant differences in clinico-pathological parameters between tumors that express AR and those that do not. If this is the case, what does this say about the role that AR plays in tumor behavior in Ethiopian BCa? How will therapies that target AR make a difference? It seems that this data supports that AR is a marker that is present in the majority of Ethiopian BCa, but it does not say anything about its prognostic usefulness. Given the number of samples and the percentage of samples that are AR positive, the authors have already agreed that the study would be stronger with the increase in number of samples. It is possible that the low number of AR negative samples are masked in the measure of differences in clinico-pathological parameters.

Therefore, while I agree that the study shows, as others have shown, that AR expression is high in ER positive BCa, I do not agree that THIS study shows that Ethiopian BCa could benefit from AR targeted treatments. It would be helpful if the study could show survival or treatment data that would allow a clearer picture of the prognostic value of AR in this population. Increasing the numbers of samples may indeed show significant differences in clinical parameters.

\>\>\> This is correct. Previous studies assessing the role of AR in breast cancer showed its positive prognostic role in hormone receptor positive BCa and its therapeutic significance in TNBC and is presented in our paper. The lack of association between AR expression and clinicaopathological parameters in our study is highly likely due to small sample size and is stated in the discussion part of the paper. We agree that survival or treatment data would give a clear picture and hope future studies to address these issues.

2\. The submitted manuscript needs significant editing regarding grammar and clarity. The first part of the discussion is almost a word-for-word repeat of the introduction instead of a summary of the study and overall findings. Also, there is no need to include a statement saying that you aren\'t going to re-hash the methods portion of the previous study. Either briefly describe the methods from the previous study with explanation of AR specific portions of these methods and reference to your previous study, or re-write the methods. It seems that you have re-written the methods anyway.

\>\>\> We agree with your concern and have edited the paper in the resubmission.

3\. Please do not use the word \"about\" when you are referring to the number of samples. Give the absolute number and describe in detail what it means for a sample to be \"evaluable.\"

\>\>\> We agree with your concern and removed the word "about" and have added more information to explain what evaluable is.
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11 Mar 2020

PONE-D-19-29283R1
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PLOS ONE

Dear Dr. Gebregzabher, 

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Please conduct a thorough grammar check and copy-editing of the entire manuscript prior to resubmission

==============================

We would appreciate receiving your revised manuscript by Apr 25 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tomi F. Akinyemiju, Ph.D

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: (No Response)

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: (No Response)

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: (No Response)

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript still has instances of awkward english and foremost this is not a novel study as there are studies assessing the expression of AR in African women. The sample size is very low and unless the survival analysis is performed we cannot mark the importance of this study. It would be impactful if the authors increase the sample size and see if there is any association of AR expression with clinicopathological parameters and perform the survival analysis to evaluate its prognostic significance.

Reviewer \#2: (No Response)

Reviewer \#3: The present study assesses the prevalence of AR-positive breast cancer cases among 112 newly diagnosed patients at a hospital in Addis Ababa, Ethiopia. The authors found that AR-positive expression was highly prevalent in this sample and that AR expression differed by subtype. The present draft is a revision from a previous submission. My review takes into consideration the previous reviewers\' comments and the authors\' corresponding revision.

Skewed continuous variables (age) should be tested for differences using a non-parametric test, such as the Wilcoxon rank-sum test.

The Materials and Methods section repeats text verbatim from earlier published work. Paraphrasing is needed. Additionally, the citation to the earlier work can be referenced once at the beginning of the Methods section and noted that this paper briefly describes those same methods.

The largest issue to address is in the Discussion when relating the present study to the literature. While differences may be due to true differences across sub-Saharan African populations, there are other possible explanations that should be addressed. This includes the use of an antibody in this study that may result in an overestimate of AR prevalence compared to other work with AR 441. Could this be why the prevalence of AR-positive BCa is higher in this study compared to others? A second factor, as the authors point out, is the cutoff score of 1% versus 10%. Is it possible with the present data to provide AR-positive prevalence using the 10% cutoff to allow for a direct comparison? Would how the participants are enrolled or the samples collected impact findings across the studies?

Continued copy-editing for grammar and style is needed.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0232519.r004

Author response to Decision Letter 1

18 Mar 2020

Reviewer 1

We thank the reviewer for the valuable comments!

Please find our responses:

1\. The manuscript still has instances of awkward english and foremost this is not a novel study as there are studies assessing the expression of AR in African women. The sample size is very low and unless the survival analysis is performed we cannot mark the importance of this study. It would be impactful if the authors increase the sample size and see if there is any association of AR expression with clinicopathological parameters and perform the survival analysis to evaluate its prognostic significance.

\>\>\> We have made an extensive language editing in this revision and hope to answer your question.

\>\>\> Concerning sample size, we acknowledge an increased sample size would provide a better insight into the study. We clearly indicated this as a one of the limitations and hope would be addressed by future studies.

\>\>\>We agree survival study could reveal a better information, but we don't have data to do survival analysis.

Reviewer 3

We thank the reviewer for valuable comments!

Please find our responses:

1\. Skewed continuous variables (age) should be tested for differences using a non-parametric test, such as the Wilcoxon rank-sum test.

\>\>\> This is correct and addressed in the revision.

2\. The Materials and Methods section repeats text verbatim from earlier published work. Paraphrasing is needed. Additionally, the citation to the earlier work can be referenced once at the beginning of the Methods section and noted that this paper briefly describes those same methods.

\>\>\> We agree with your concern and have edited the paper in the revision.

3\. The largest issue to address is in the Discussion when relating the present study to the literature. While differences may be due to true differences across sub-Saharan African populations, there are other possible explanations that should be addressed. This includes the use of an antibody in this study that may result in an overestimate of AR prevalence compared to other work with AR 441. Could this be why the prevalence of AR-positive BCa is higher in this study compared to others? A second factor, as the authors point out, is the cutoff score of 1% versus 10%. Is it possible with the present data to provide AR-positive prevalence using the 10% cutoff to allow for a direct comparison? Would how the participants are enrolled or the samples collected impact findings across the studies?

\>\>\> We agree with you concerning the antibody clone and have included your indication in the revision.

\>\>\> AR is currently interpreted at a cutoff of 1% and it is our hope that more studies would be conducted on AR in this continent and a future comparative study would possibly come up with a better insight.

With kind regards!

Endale Hadgu
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Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia: A cross sectional study

PLOS ONE

Dear Dr. Gebregzabhar,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by June 27, 2020. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tomi F. Akinyemiju, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Whole sentences and sections from the BMC Women\'s Health paper are still presented in the current manuscript verbatim. Even while referencing the previous manuscript and stating the overlap, there still needs to be extensive paraphrasing and re-wording so that the text is not exactly the same across the two publications. If this is done, there is no need to include this sentence:

\'Therefore, the description of the methods presented here though rephrased may overlap with our previous paper with the exception of AR specific information.\'

Further grammatical editing is still highly suggested to improve the quality of the writing/language

\[Note: HTML markup is below. Please do not edit.\]

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0232519.r006

Author response to Decision Letter 2

1 Apr 2020

Dear Editors,

We would like to thank you again for giving us the opportunity to re-submit our manuscript to PLOS ONE. Thank you very much for reviewing the paper and giving valuable feedback. We have addressed the academic editor comments in the resubmitted draft, with changes highlighted. We would like to thank the academic editor for their constructive ideas which have helped improve comprehension for the audience.

We provide here a letter with a point-by-point response to the concerns:

Response to academic editor:

1\. Whole sentences and sections from the BMC Women\'s Health paper are still presented in the current manuscript verbatim. Even while referencing the previous manuscript and stating the overlap, there still needs to be extensive paraphrasing and re-wording so that the text is not exactly the same across the two publications. If this is done, there is no need to include this sentence:

\'Therefore, the description of the methods presented here though rephrased may overlap with our previous paper with the exception of AR specific information.\'

Further grammatical editing is still highly suggested to improve the quality of the writing/language

\>\>\> We have made the language editing as per your advice in this revision and hope to answer your question.

With kind regards!

Endale Hadgu
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PONE-D-19-29283R3

Dear Dr. Gebregzabher,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Tomi F. Akinyemiju, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

22 Apr 2020

PONE-D-19-29283R3

Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia: A cross sectional study

Dear Dr. Gebregzabher:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tomi F. Akinyemiju

Academic Editor

PLOS ONE
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